


December 17, 2015

CIRM

CALIFORNIA'S STEM CELL AGENCY



President's Report

C. Randal Mills, Ph.D.

President and Chief Executive Officer
California Institute for Regenerative Medicine

Topics



DISCOVERY
TRANSLATIONAL
CLINICAL
EDUCATION
INFRASTRUCTURE

- Mission
- FY 1Q16 Financial Update
- CIRM 2.0 Clinical Stage Program Review
- New Home

Our Mission

To accelerate stem cell treatments to patients with unmet medical needs.



FINANCIAL UPDATE FOR FY- 4Q15 AND FULL YEAR 2015

The Administrative Bucket



Administrative Budget
\$180 Million

**Five more years of funding
available at this rate**

- \$105 million spent
- \$75 million remaining
- Current spend rate of \$15-16 million per year

The Award Bucket




Sufficient to last into FY 2020

- \$2 billion awarded or spent
- \$759 million uncommitted
- Planned NET commitment rate of \$170 million per year
 - \$190 million in new awards
 - \$20 million in reductions


CIRM's \$2.75 Billion Award Budget

1Q16 Activity



CIRM's \$2.75 Billion Award Budget

Full Year Activity



Award Return Rate of 22%



CLINICAL STAGE PORTFOLIO REVIEW

Evaluating CIRM 2.0 Clinical Program

CIRM 2.0 Summary

- Total Clinical Applications Received: 28
- Applications Passing Eligibility: 19
- Applications with Final GWG Dispositions: 16
- Applications Under Review: 3
- Applications Recommended for Funding: 6 (38%)

Evaluating CIRM 2.0 Clinical Program

CIRM 2.0 Scoring

Initial Review Scores:

- Tier 1: 3
- Tier 2: 7 (2 pending re-review)
- Tier 3: 8

Final Review Scores:

- Tier 1: 6
- Tier 2: 1 (did not resubmit)
- Tier 3: 9

Evaluating CIRM 2.0 Clinical Program


Stages of Development Funded

- Phase III: 2
- Phase II: 1
- Phase I: 1
- IND Seeking: 2

Where We Are Today

\$1.3 billion invested in disease specific research including 15 clinical trials

- HIV/AIDS (3)
- Solid Tumors (2)
- Heart Failure
- Leukemia
- Sickle Cell Anemia
- Spinal Cord Injury
- Type 1 Diabetes
- Macular Degeneration
- Retinitis Pigmentosa
- Malignant Melanoma
- Chronic Granulomatous Disease
- Glioblastoma



New Process for Portfolio Updates

Clinical Program

For Clinical Stage Programs (Pre-IND+)

- High-level summary list (currently 26 projects)
- Broken down by disease area
- GWG to review material changes monthly
- Recommend action where appropriate
- Board to be updated quarterly portfolio developments



CIRM'S NEW HOME

1999 Harrison Street, Oakland

